ArticleNanomedicine (London, England)2026
Precise atorvastatin delivery by cardiac homing peptide functionalized nanoliposomes for myocardial damage repair after myocardial infarction.
Article in Nanomedicine (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo develop a novel lipid nanoparticle (Ato@DSPE-PEG-CHP) for targeted delivery to ischemic myocardium to treat myocardial infarction.
methodsAto@DSPE-PEG-CHP was prepared using the thin-film dispersion method. Physicochemical properties were characterized by transmission electron microscope (TEM) and dynamic light scattering (DLS).
resultsAto@DSPE-PEG-CHP with uniform morphology, excellent dispersibility, and high stability were successfully prepared. This material can target myocardial ischemia sites both
conclusionAto@DSPE-PEG-CHP specifically targeted ischemic myocardium, alleviated damage through its anti-inflammatory and antioxidant effects, and demonstrated superior efficacy and safety, presenting a promising treatment strategy for MI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.